Cancer discovery
-
Due to the COVID-19 pandemic, oncologists have had to balance patients' need for treatment with their risk of contracting the disease, sometimes leading them to adjust standard treatment and/or rethink its timing. These decisions have been largely informed by guidelines, research, and shared decision-making-and their complexity led one group to develop a tool that might help.
-
The COVID-19 pandemic has caused widespread disruption of cancer clinical trials due to the restrictions on nonessential services and the reallocation of resources, and at the same time the urgent global effort toward discovering therapies that treat or prevent COVID-19 infection has led to shortening of traditional regulatory timelines. This experience should stimulate similar urgency in the way future cancer research is conducted.